NCT02194049View on ClinicalTrials.gov

Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

June 30, 2016

Conditions
Extensive Stage Small Cell Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

BKM120

Given PO

DRUG

cisplatin

Given IV

DRUG

etoposide

Given IV

Trial Locations (1)

95817

University of California at Davis Cancer Center, Sacramento

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, Davis

OTHER